• Product name

    Anti-PDGFC antibody - C-terminal
    See all PDGFC primary antibodies
  • Description

    Mouse polyclonal to PDGFC - C-terminal
  • Host species

  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse, Rat, Chicken
  • Immunogen

    Recombinant fragment (GST-tag) corresponding to Human PDGFC aa 236-345 (C terminal). NCBI Accession No. NP_057289.


    Database link: Q9NRA1

  • Positive control

    • 293 cell lysate; recombinant Human PDGFC protein (immunogen).



Our Abpromise guarantee covers the use of ab194504 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/2500. Predicted molecular weight: 39 kDa.


  • Function

    Potent mitogen and chemoattractant for cells of mesenchymal origin. Binding of this growth factor to its affinity receptor elicits a variety of cellular responses. Appears to be involved in the three stages of wound healing: inflammation, proliferation and remodeling. Involved in fibrotic processes, in which transformation of interstitial fibroblasts into myofibroblasts plus collagen deposition occurs. Acts as a specific ligand for alpha platelet-derived growth factor receptor homodimer, and alpha and beta heterodimer. Binding to receptors induces their activation by tyrosine phosphorylation. The CUB domain has mitogenic activity in coronary artery smooth muscle cells, suggesting a role beyond the maintainance of the latency of the PDGF domain. In the nucleus, PDGFC seems to have additional function. Seems to be involved in palatogenesis.
  • Tissue specificity

    Expressed in the fallopian tube, vascular smooth muscle cells in kidney, breast and colon and in visceral smooth muscle of the gastrointestinal tract. Highly expressed in retinal pigment epithelia. Expressed in medulloblastoma. In the kidney, constitutively expressed in parietal epithelial cells of Bowman's capsule, tubular epithelial cells and in arterial endothelial cells (at protein level). Highly expressed in the platelets, prostate, testis and uterus. Higher expression is observed in uterine leiomyomata. Weaker expression in the spleen, thymus, heart, pancreas, liver, ovary cells and small intestine, and negligible expression in the colon and peripheral blood leukocytes.
  • Sequence similarities

    Belongs to the PDGF/VEGF growth factor family.
    Contains 1 CUB domain.
  • Developmental stage

    In the fetal kidney, detected in the developing mesangium, ureteric bud epithelium and the undifferentiated mesenchyme (at protein level).
  • Post-translational

    Proteolytic removal of the N-terminal CUB domain releasing the core domain is necessary for unmasking the receptor-binding epitopes of the core domain. Cleavage after basic residues in the hinge region (region connecting the CUB and growth factor domains) gives rise to the receptor-binding form. Cleaved by PLAT and PLG.
    Sumoylated by SUMO1.
  • Cellular localization

    Cytoplasm. Secreted. Nucleus. Cytoplasmic granule. Sumoylated form is predominant in the nucleus. Stored in alpha granules in platelets. Membrane associated when bound to receptors.
  • Information by UniProt
  • Database links

  • Alternative names

    • Fallotein antibody
    • hSCDGF antibody
    • PDGF-C antibody
    • PDGFC antibody
    • PDGFC latent form antibody
    • PDGFC receptor-binding form antibody
    • PDGFC_HUMAN antibody
    • Platelet derived growth factor C antibody
    • Platelet-derived growth factor C, receptor-binding form antibody
    • SCDGF antibody
    • Secretory growth factor like protein antibody
    • Secretory growth factor like protein fallotein antibody
    • Spinal cord derived growth factor antibody
    • Spinal cord-derived growth factor antibody
    • VEGF E antibody
    • VEGF-E antibody
    see all


  • Anti-PDGFC antibody - C-terminal (ab194504) at 1/1000 dilution + recombinant Human PDGFC protein (immunogen) at 0.2 µg

    Developed using the ECL technique.

    Predicted band size: 39 kDa

    Predicted MWt of immunogen: 38.21 KDa.

  • Anti-PDGFC antibody - C-terminal (ab194504) at 1/500 dilution + 293 cell lysate at 50 µg

    Developed using the ECL technique.

    Predicted band size: 39 kDa


ab194504 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab194504.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact partnerships@abcam.com

Sign up